Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Amortization of Deferred Charges (2019 - 2020)

Avidity Biosciences (RNA) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $20000.0 as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Amortization of Deferred Charges changed N/A year-over-year to $20000.0, compared with a TTM value of $20000.0 through Mar 2021, changed N/A, and an annual FY2020 reading of $29000.0, down 59.15% over the prior year.
  • Amortization of Deferred Charges was $20000.0 for Q2 2020 at Avidity Biosciences, up from $9000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $27000.0 in Q3 2019 and bottomed at $9000.0 in Q1 2020.